[1]
|
Pater, L., Melchior, P., Rübe, C., et al. (2021) Wilms Tumor. Pediatric Blood & Cancer, 68, e28257.
https://doi.org/10.1002/pbc.28257
|
[2]
|
Vujanic, G.M., Gessler, M., Ooms, A., et al. (2018) The UMBRELLA SIOP-RTSG 2016 Wilms Tumour Pathology and Molecular Biology Protocol. Nature Reviews Urology, 15, 693-701. https://doi.org/10.1038/s41585-018-0100-3
|
[3]
|
Fernandez, C.V., Mullen, E.A., Chi, Y.Y., et al. (2018) Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report from the Children’s Oncology Group Study AREN0532. Journal of Clinical Oncology, 36, 254-261. https://doi.org/10.1200/JCO.2017.73.7999
|
[4]
|
Dix, D.B., Seibel, N.L., Chi, Y.Y., et al. (2018) Treatment of Stage IV Favorable Histology Wilms Tumor with Lung Metastases: A Report from the Children’s Oncology Group AREN0533 Study. Journal of Clinical Oncology, 36, 1564-1570. https://doi.org/10.1200/JCO.2017.77.1931
|
[5]
|
Aldrink, J.H., Heaton, T.E., Dasgupta, R., et al. (2019) Update on Wilms Tumor. Journal of Pediatric Surgery, 54, 390-397. https://doi.org/10.1016/j.jpedsurg.2018.09.005
|
[6]
|
Ehrlich, P.F. anderson, J.R., Ritchey, M.L., et al. (2013) Clinicopathologic Findings Predictive of Relapse in Children with Stage III Favorable-Histology Wilms Tumor. Journal of Clinical Oncology, 31, 1196-1201.
https://doi.org/10.1200/JCO.2011.41.1165
|
[7]
|
Zhang, Y., Song, H., Yang, Y., Sun, N., Zhang, W. and Huang, C. (2021) Preoperative Wilms Tumor Rupture in Children. International Urology and Nephrology, 53, 619-625. https://doi.org/10.1007/s11255-020-02706-5
|
[8]
|
Daw, N.C., Chi, Y.Y., Kalapurakal, J.A., Kim, Y., Hoffer, F.A., Geller, J.I., et al. (2020) Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children’s Oncology Group AREN0321 Study. Journal of Clinical Oncology, 38, 1558-1568.
https://doi.org/10.1200/JCO.19.01265
|
[9]
|
杨文萍, 武海燕, 张文, 等. 儿童肾母细胞瘤病理诊断共识[J]. 中华病理学杂志, 2017, 46(3): 149-154.
|
[10]
|
Bhutani, N., Kajal, P. and Sharma, U. (2021) Many Faces of Wilms Tumor: Recent Advances and Future Directions. Annals of Medicine and Surgery (London), 64, Article ID: 102202. https://doi.org/10.1016/j.amsu.2021.102202
|
[11]
|
Daw, N.C., Chi, Y., Kim, Y., Mullen, E.A., Kalapurakal, J.A., Tian, J., et al. (2019) Treatment of Stage I Anaplastic Wilms’ Tumour: A Report from the Children’s Oncology Group AREN0321 Study. European Journal of Cancer, 118, 58-66. https://doi.org/10.1016/j.ejca.2019.05.033
|
[12]
|
Fajardo, R.D., den Heuvel Eibrink, M.M., Tinteren, H., Spreafico, F., Acha, T., et al. (2019) Is Radiotherapy Required in First-Line Treatment of Stage I Diffuse Anaplastic Wilms Tumor? A Report of SIOP-RTSG, AIEOP, JWiTS, and UKCCSG. Pediatric Blood & Cancer, 67, e28039. https://doi.org/10.1002/pbc.28039
|
[13]
|
Vujani, G.M., Sandstedt, B., Harms, D., Kelsey, A., Leuschner, I. and de Kraker, J. (2002) Revised International Society of Paediatric Oncology (SIOP) Working Classification of Renal Tumors of Childhood. Medical and Pediatric Oncology, 38, 79-82. https://doi.org/10.1002/mpo.1276
|
[14]
|
Pasqualini, C., Furtwängler, R., van Tinteren, H., Teixeira, R.A.P., et al. (2020) Outcome of Patients with Stage IV High-Risk Wilms Tumour Treated According to the SIOP2001 Protocol: A Report of the SIOP Renal Tumour Study Group. European Journal of Cancer, 128, 38-46. https://doi.org/10.1016/j.ejca.2020.01.001
|
[15]
|
Groenendijk, A., Spreafico, F., de Krijger, R.R., et al. (2021) Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature. Cancers (Basel), 13, 3142. https://doi.org/10.3390/cancers13133142
|
[16]
|
Nelson, M.V., van den Heuvel-Eibrink, M.M., Graf, N. and Dome, J.S. (2021) New Approaches to Risk Stratification for Wilms Tumor. Current Opinion in Pediatrics, 33, 40-48. https://doi.org/10.1097/MOP.0000000000000988
|
[17]
|
Hol, J.A., Lopez-Yurda, M.I., Van Tinteren, H., Van Grotel, M., Godzinski, J., Vujanic, G., et al. (2019) Prognostic Significance of Age in 5631 Patients with Wilms Tumour Prospectively Registered in International Society of Paediatric Oncology (SIOP) 93-01 and 2001. PLOS ONE, 14, e221373. https://doi.org/10.1371/journal.pone.0221373
|
[18]
|
Pritchard-Jones, K., Kelsey, A., Vujanic, G., Imeson, J., Hutton, C. and Mitchell, C. (2003) Older Age Is an Adverse Prognostic Factor in Stage I, Favorable Histology Wilms’ Tumor Treated with Vincristine Monochemotherapy: A Study by the United Kingdom Children’s Cancer Study Group, Wilm’s Tumor Working Group. Journal of Clinical Oncology, 21, 3269-3275. https://doi.org/10.1200/JCO.2003.01.062
|
[19]
|
Lopyan, N.M. and Ehrlich, P.F. (2021) Surgical Management of Wilms Tumor (Nephroblastoma) and Renal Cell Carcinoma in Children and Young Adults. Surgical Oncology Clinics of North America, 30, 305-323.
https://doi.org/10.1016/j.soc.2020.11.002
|
[20]
|
Haruta, M., Arai, Y., Okita, H., Tanaka, Y., et al. (2019) Combined Genetic and Chromosomal Characterization of Wilms Tumors Identifies Chromosome 12 Gain as a Potential New Marker Predicting a Favorable Outcome. Neoplasia, 21, 117-131. https://doi.org/10.1016/j.neo.2018.10.007
|
[21]
|
Bu, Q., He, H., Fan, D., Lyu, J., Pan, Z. and You, H. (2018) Association between Loss of Heterozygosity of Chromosome 16q and Survival in Wilms’ Tumor: A Meta-Analysis. Pathology—Research and Practice, 214, 1772-1777.
https://doi.org/10.1016/j.prp.2018.08.010
|
[22]
|
Holmquist Mengelbier, L., Lindell-Munther, S., Yasui, H., et al. (2019) The Iroquois Homeobox Proteins IRX3 and IRX5 Have Distinct Roles in Wilms Tumour Development and Human Nephrogenesis. The Journal of Pathology, 247, 86-98. https://doi.org/10.1002/path.5171
|
[23]
|
Mengelbier, L.H., Karlsson, J., Lindgren, D., Øra, I., Isaksson, M., Frigyesi, I., et al. (2010) Deletions of 16q in Wilms Tumors Localize to Blastemal-Anaplastic Cells and Are Associated with Reduced Expression of the IRXB Renal Tubulogenesis Gene Cluster. The American Journal of Pathology, 177, 2609-2621.
https://doi.org/10.2353/ajpath.2010.100130
|
[24]
|
Dix, D.B., Fernandez, C.V., Chi, Y.Y., Mullen, E.A., Geller, J.I., et al. (2019) Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children’s Oncology Group AREN0532 and AREN0533 Study Report. Journal of Clinical Oncology, 37, 2769-2777. https://doi.org/10.1200/JCO.18.01972
|
[25]
|
Park, J.E., Noh, O.K., Lee, Y., Choi, H.S., Han, J.W., Hahn, S.M., et al. (2020) Loss of Heterozygosity at Chromosome 16q Is a Negative Prognostic Factor in Korean Pediatric Patients with Favorable Histology Wilms Tumor: A Report of the Korean Pediatric Hematology Oncology Group (K-PHOG). Cancer Research and Treatment, 52, 438-445.
https://doi.org/10.4143/crt.2019.313
|
[26]
|
Bown, N., Cotterill, S.J., Roberts, P., Griffiths, M., Larkins, S., et al. (2002) Cytogenetic Abnormalities and Clinical Outcome in Wilms Tumor: A Study by the U.K. Cancer Cytogenetics Group and the U.K. Children’s Cancer Study Group. Medical and Pediatric Oncology, 38, 11-21. https://doi.org/10.1002/mpo.1258
|
[27]
|
Gratias, E.J., Dome, J.S., Jennings, L.J., Chi, Y., Tian, J. anderson, J., et al. (2016) Association of Chromosome 1q Gain with Inferior Survival in Favorable-Histology Wilms Tumor: A Report from the Children’s Oncology Group. Journal of Clinical Oncology, 34, 3189-3194. https://doi.org/10.1200/JCO.2015.66.1140
|
[28]
|
Gratias, E.J., Jennings, L.J. anderson, J.R., Dome, J.S., Grundy, P. and Perlman, E.J. (2013) Gain of 1q Is Associated with Inferior Event-Free and Overall Survival in Patients with Favorable Histology Wilms Tumor: A Report from the Children’s Oncology Group. Cancer, 119, 3887-3894. https://doi.org/10.1002/cncr.28239
|
[29]
|
Treger, T.D., Chowdhury, T., Pritchard-Jones, K. and Behjati, S. (2019) The Genetic Changes of Wilms Tumour. Nature Reviews Nephrology, 15, 240-251. https://doi.org/10.1038/s41581-019-0112-0
|
[30]
|
Madanat-Harjuoja, L.M., Renfro, L.A., Klega, K., Tornwall, B., Thorner, A.R., et al. (2022) Circulating Tumor DNA as a Biomarker in Patients with Stage III and IV Wilms Tumor: Analysis from a Children’s Oncology Group Trial, AREN0533. Journal of Clinical Oncology, 40, 3047-3056. https://doi.org/10.1200/JCO.22.00098
|
[31]
|
Hol, J.A., Kuiper, R.P., van Dijk, F., Waanders, E., van Peer, S.E., et al. (2022) Prevalence of (Epi)genetic Predisposing Factors in a 5-Year Unselected National Wilms Tumor Cohort: A Comprehensive Clinical and Genomic Characterization. Journal of Clinical Oncology, 40, 1892-1902. https://doi.org/10.1200/JCO.21.02510
|
[32]
|
Maciaszek, J.L., Oak, N. and Nichols, K.E. (2020) Recent Advances in Wilms’ Tumor Predisposition. Human Molecular Genetics, 29, R138-R149. https://doi.org/10.1093/hmg/ddaa091
|
[33]
|
Ortiz, M.V., Ahmed, S., Burns, M., Henssen, A.G., Hollmann, T.J., MacArthur, I., et al. (2019) Prohibitin Is a Prognostic Marker and Therapeutic Target to Block Chemotherapy Resistance in Wilms’ Tumor. JCI Insight, 4, e127098.
https://doi.org/10.1172/jci.insight.127098
|
[34]
|
Taskinen, S., Leskinen, O., Lohi, J., Koskenvuo, M. and Taskinen, M. (2019) Effect of Wilms Tumor Histology on Response to Neoadjuvant Chemotherapy. Journal of Pediatric Surgery, 54, 771-774.
https://doi.org/10.1016/j.jpedsurg.2018.05.010
|
[35]
|
Vujanić, G.M., D’Hooghe, E., Graf, N., Vokuhl, C., Al Saadi, R., et al. (2021) Prognostic Significance of Histopathological Response to Preoperative Chemotherapy in Unilateral Wilms’ Tumor: An Analysis of 899 Patients Treated on the SIOP WT 2001 Protocol in the UK-CCLG and GPOH Studies. International Journal of Cancer, 149, 1332-1340.
https://doi.org/10.1002/ijc.33707
|
[36]
|
Verschuur, A., van Tinteren, H., Graf, N., Bergeron, C., Sandstedt, B. and de Kraker, J. (2012) Treatment of Pulmonary Metastases in Children with Stage IV Nephroblastoma with Risk-Based Use of Pulmonary Radiotherapy. Journal of Clinical Oncology, 30, 3533-3539. https://doi.org/10.1200/JCO.2011.35.8747
|